RecruitingPhase 2NCT07271186

Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of ANGPTL3 Inhibition With Either Small-Interfering RNA Alone or in Combination With an ANGPTL3 Antibody in Participants With Diabetic Kidney Disease

Sponsor

Regeneron Pharmaceuticals

Enrollment

270 participants

Start Date

Jan 9, 2026

Study Type

INTERVENTIONAL

Conditions

Diabetic Kidney Disease (DKD)

Summary

This study is researching experimental drugs called ALN-ANG3 and evinacumab (called "study drugs"). The study is focused on participants who have diabetic kidney disease. The aim of the study is to see how safe and effective the study drugs are. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a drug that blocks a protein called ANGPTL3, which plays a role in kidney disease and fat metabolism. Researchers want to know if blocking this protein can protect the kidneys in people with type 2 diabetes who already have significant protein in their urine — a sign of kidney damage. **You may be eligible if...** - You have type 2 diabetes and are receiving treatment or lifestyle interventions for blood sugar control - Your HbA1c (a 3-month blood sugar average) is between 6.5% and 10% - Your kidneys are working at a reduced but not severely impaired level (eGFR between 30 and 90) - You have a high amount of protein in your urine (UACR between 500 and 5000 mg/g) **You may NOT be eligible if...** - Your kidney disease is caused by something other than diabetes - Your kidney function is too severely reduced - You have recently had a heart attack or stroke - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGALN-ANG3

Administered per the protocol

DRUGEvinacumab

Administered per the protocol

DRUGALN-ANG3 placebo

Administered per the protocol

DRUGEvinacumab placebo

Administered per the protocol

Locations(47)

Apogee Clinical Research, LLC

Huntsville, Alabama, United States

Applied Research Center of Arkansas

Little Rock, Arkansas, United States

AME Clinical Research

Huntington Beach, California, United States

Amicis Research Center

Northridge, California, United States

FOMAT - Vista del Mar Medical Group

Oxnard, California, United States

Central Coast Nephrology

Salinas, California, United States

North America Research Institute

San Dimas, California, United States

Amicis Research Center

Santa Clarita, California, United States

Valiance Clinical Research

Tarzana, California, United States

Amicis Research Center

Valencia, California, United States

National Institute of Clinical Research, Inc.

Victorville, California, United States

D&H Doral Research Center

Doral, Florida, United States

AGA Clinical Trials

Hialeah, Florida, United States

Convenient Medical Center

Hialeah, Florida, United States

Elixia Hollywood

Hollywood, Florida, United States

D&H Pompano Research Center

Margate, Florida, United States

LCC Medical Research Institute

Miami, Florida, United States

D&H National Research Centers, Inc

Miami, Florida, United States

Regenerate Primary Medical Research, LLC

Miami, Florida, United States

Ocean Blue Medical Research Center - Internal Medicine

Miami Springs, Florida, United States

Innovia Research Center

Miramar, Florida, United States

Bolanos Clinical Research

Pembroke Pines, Florida, United States

Progressive Medical Research

Port Orange, Florida, United States

CDC Research Institute

Port Saint Lucie, Florida, United States

D&H Tamarac Research Center

Tamarac, Florida, United States

Metabolic Research Institute

West Palm Beach, Florida, United States

Privia Medical Group of Georgia, LLC

Savannah, Georgia, United States

Research by Design, LLC - Internal Medicine

Chicago, Illinois, United States

Elixia Michigan Kidney Consultants

Pontiac, Michigan, United States

Elixia MNA

City of Saint Peters, Missouri, United States

Clinical Research Consultants, LLC

Kansas City, Missouri, United States

DaVita Clinical Research

Las Vegas, Nevada, United States

Velocity Clinical Research

Binghamton, New York, United States

CHEAR Center LLC

The Bronx, New York, United States

Brookview Hills Research Associates, LLC

Winston-Salem, North Carolina, United States

Northeast Clinical Research Center

Bethlehem, Pennsylvania, United States

Suburban Research Associates

West Chester, Pennsylvania, United States

Southeast Renal Research Institute

Chattanooga, Tennessee, United States

Arlington Nephrology, PLLC.

Arlington, Texas, United States

M3 Wake Research Dallas - Internal Medicine

Dallas, Texas, United States

El Paso Kidney Specialists-Davita Clinical Research

El Paso, Texas, United States

Juno Research, LLC

Houston, Texas, United States

Clinical Trial Network, LLC

Houston, Texas, United States

Gulf Coast Clinical Research

Katy, Texas, United States

R & H Clinical Research, Inc.

Katy, Texas, United States

Sunbeam Clinical Research

McKinney, Texas, United States

Clinical Advancement Center

San Antonio, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07271186

Related Trials

Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease

NCT069698076 locations

Efficacy and Safety Study of Isuzinaxib in Subjects With DKD

NCT0696209820 locations